Ricevi le ultime notizie sulle azioni Skye Bioscience con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SKYE

Ultime notizie per

Skye Bioscience

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience Inc

Skye Bioscience Inc Ordinary Shares

Skye Petroleum Inc

Press Releases

Skye Bioscience to Participate in Upcoming Investment Conferences

News

Health Care

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

General

Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Earnings

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye's CB1 Inhibitor, Nimacimab,  Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

SKYE

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Agenus

Anika Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Biomea Fusion

C4 Therapeutics

Climb Bio

Cardiff Oncology

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MDxHealth

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Nuvectis Pharma

Oncolytics Biotech

Pyxis Oncology

AVITA Medical

TScan Therapeutics

Tevogen Bio Holdings

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Evercore ISI Group

JMP Securities

Craig-Hallum

Citizens Capital Markets

Comments

Skye Bioscience Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO